Cell Therapeutics' Pixuvri gets French marketing nod to treat aggressive B ... pharmabiz.com The European Medicines Agency's (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have ... |
